MicroRNAs(miRNAs)are endogenous single-stranded non-coding RNAs approximately 22 nt in length,which play a regulatory role in various biological processes by targeting and inhibiting protein-coding gene transcripts.Am...MicroRNAs(miRNAs)are endogenous single-stranded non-coding RNAs approximately 22 nt in length,which play a regulatory role in various biological processes by targeting and inhibiting protein-coding gene transcripts.Among the wide range of miRNAs,miR-668 exhibits abnormal expression patterns in different diseases,including head and neck squamous cell carcinoma(HNSC),hepatocellular carcinoma(HCC),breast cancer(BrC),ischemic acute kidney injury(ischemic AKI),myocardial infarction(MI),ischemic stroke(IS),Parkinson’s disease(PD),smoking-related interstitial fibrosis(SRIF),premature aging,and non-segmental vitiligo(NSV),among others.The expression of miR-668 is regulated by various upstream factors,including other non-coding RNAs and endogenous proteins.Functionally,miR-668 targets 6 protein-coding genes(SDF-1,Dvl1,BTG2,MTFP1,FHIT,and NFKBIA)and is involved in 3 signaling pathways:the Drp signaling pathway,NF-κB signaling pathway,and NLRP3 signaling pathway.Notably,miR-668 has contrasting effects depending on the context;it can promote the development and metastasis of HCC and induce radiation resistance in BrC cells,while also promoting aging and inhibiting HNSC progression in human keratinocytes.Furthermore,miR-668 exhibits anti-apoptotic effects,alleviates ischemia/reperfusion injury,improves intracerebral expansion,relieves hydrocephalus,and has prognostic value in gastric cancer(GC),HCC,and BrC,with high expression predicting poor outcomes.Notably,the cancer drugs melatonin and Pterostilbene(Ptero)exert their therapeutic effects by modulating miR-668.Future studies should focus on validating the reliability of miR-668 as a biomarker and elucidating the specific mechanisms through which miR-668 participates in cancer therapy.展开更多
基金supported by the Qiantang Scholars Fund in Hangzhou City University of China(No.210000-581835).
文摘MicroRNAs(miRNAs)are endogenous single-stranded non-coding RNAs approximately 22 nt in length,which play a regulatory role in various biological processes by targeting and inhibiting protein-coding gene transcripts.Among the wide range of miRNAs,miR-668 exhibits abnormal expression patterns in different diseases,including head and neck squamous cell carcinoma(HNSC),hepatocellular carcinoma(HCC),breast cancer(BrC),ischemic acute kidney injury(ischemic AKI),myocardial infarction(MI),ischemic stroke(IS),Parkinson’s disease(PD),smoking-related interstitial fibrosis(SRIF),premature aging,and non-segmental vitiligo(NSV),among others.The expression of miR-668 is regulated by various upstream factors,including other non-coding RNAs and endogenous proteins.Functionally,miR-668 targets 6 protein-coding genes(SDF-1,Dvl1,BTG2,MTFP1,FHIT,and NFKBIA)and is involved in 3 signaling pathways:the Drp signaling pathway,NF-κB signaling pathway,and NLRP3 signaling pathway.Notably,miR-668 has contrasting effects depending on the context;it can promote the development and metastasis of HCC and induce radiation resistance in BrC cells,while also promoting aging and inhibiting HNSC progression in human keratinocytes.Furthermore,miR-668 exhibits anti-apoptotic effects,alleviates ischemia/reperfusion injury,improves intracerebral expansion,relieves hydrocephalus,and has prognostic value in gastric cancer(GC),HCC,and BrC,with high expression predicting poor outcomes.Notably,the cancer drugs melatonin and Pterostilbene(Ptero)exert their therapeutic effects by modulating miR-668.Future studies should focus on validating the reliability of miR-668 as a biomarker and elucidating the specific mechanisms through which miR-668 participates in cancer therapy.
